Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences

Table 1 Abridged clinicopathological features of patient-matched primary and local recurrence tumor cohort

Case	Age Dx	Hist	Stage	ER Prim	PR Prim	HER2 Prim	Endo Tx	HER2 Tx	Radio Tx	Chemo Tx	DFS	SPLR	Vital status	OS
ERLR_01	36	IDC/ILC Mixed	I	Pos	Pos	Neg	Yes	No	Yes	Yes	86	132	Alive	218
ERLR_02	54	IDC	IIA	Pos	Neg	Pos	Yes	No	Yes	Yes	61	141	Alive	203
ERLR_03	74	IDC	I	Pos	Pos	NA	Yes	No	Yes	No	76	128	Dead	204
ERLR_05	54	IDC	IIA	Pos	Pos	Neg	Yes	No	Yes	Yes	69	85	Dead	155
ERLR_07	58	IDC	I	Pos	Pos	Pos	Yes	No	Yes	No	19	179	Alive	199
ERLR_08	52	IDC	IA	Pos	Pos	Pos	Yes	Yes	Yes	Yes	37	38	Alive	75
ERLR_09	51	IDC	IA	Pos	Pos	Neg	Yes	No	Yes	No	25	46	Alive	71
ERLR_12	47	IMC	IIA	Pos	Pos	Neg	Yes	No	No	No	26	34	Alive	61
ERLR_14	50	IDC	IA	Pos	Pos	Neg	Yes	No	NA	No	3	26	Alive	29
ERLR_15	65	IDC	IIIC	Pos	Pos	Neg	Yes	No	Yes	No	10	27	Alive	38
ERLR_19	49	IDC w/ lobular features	IIA	Pos	Pos	Neg	Yes	No	No	No	52	8	Alive	61
ERLR_20	42	IDC	IIIA	Pos	Pos	Pos	Yes	Yes	Yes	Yes	59	44	Dead	104

Abbreviations: Dx diagnosis, Hist histology, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2, Endo endocrine, Tx therapy, DFS disease-free survival, SPLR survival post-local recurrence, OS overall survival, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mucinous carcinoma

ISSN: 1465-542X